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Take Home Message 
Patients with asthma hospitalised with influenza are commonly female and lack 
classical type 2 nasal mucosal inflammation. Compared to others hospitalised with 
influenza, they have a good prognosis with enhanced type 1 interferon production and 
reduced systemic inflammation. 
 





Patients with asthma are at risk of hospitalisation with influenza, but the reasons for 
this predisposition are unknown. 
 
Study setting 
A prospective observational study of adults with PCR-confirmed influenza in 11 UK 
hospitals, measuring nasal, nasopharyngeal and systemic immune mediators and 
whole-blood gene expression. 
 
Results 
Of 133 admissions, 40 (30%) had previous asthma; these were more often female 
(70% vs 38.7%, OR 3.69, 95% CI 1.67 to 8.18, P = 0.0012), required less mechanical 
ventilation (15% vs 37.6%, χ2 6.78, P=0.0338) and had shorter hospital stays (mean 
8.3 vs 15.3 d, P=0.0333) than those without. In patients without asthma, severe 
outcomes were more frequent in those given corticosteroids (OR=2.63, 95% CI=1.02-
6.96, P=0.0466) or presenting >4 days after disease onset (OR 5.49, 95% CI 2.28–
14.03, P=0.0002). Influenza vaccination in at-risk groups (including asthma) were 
lower than intended by national policy and the early use of antiviral medications were 
less than optimal. Mucosal immune responses were equivalent between groups. 
Those with asthma had higher serum IFN-α but lower serum TNF, IL-5, IL-6, CXCL8, 
CXCL9, IL-10, IL-17 and CCL2 levels (all P<0.05); both groups had similar serum IL-
13, total IgE, periostin and blood eosinophil gene expression levels. Asthma diagnosis 





Asthma is common in those hospitalised with influenza, but may not represent 
classical Type 2-driven disease. Those admitted with influenza tend to be female with 
mild serum inflammatory responses, increased serum IFN-α levels and good clinical 
outcomes. 
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Influenza viruses cause a continuous threat to global health, mutating and spreading 
in both human and animal populations. The Influenza Clinical Information Network 
(FLU-CIN) reported that asthma was the commonest pre-existing risk factor for 
hospitalization, being present in 25.3% of 1,520 patients admitted with influenza A 
infection[1]. This apparent increased risk is reported in other studies which 
paradoxically also show that individuals with asthma experience less severe outcomes 
and are discharged earlier from hospital than those without asthma[2, 3]. There have 
been many studies of immune responses to influenza infection[4, 5], but none has 
focussed on characterizing the effect of asthma in the host responses to natural 
influenza. 
 
The Mechanisms of Severe Acute Influenza Consortium (MOSAIC) recruited patients 
with clinical influenza presenting to hospitals in London and Liverpool (UK) during the 
winters of 2009/10 and 2010/11, periods of intense influenza activity. We previously 
reported enrichment for a host genetic variant of the interferon-inducible 
transmembrane protein 3 (IFITM3) allele SNP rs12252-C in hospitalized patients[6] 
and that circulating influenza viruses evolved and change in character over time[7] 
and the progression of whole-blood transcriptional signatures and mediator levels from 
interferon-induced to neutrophil-associated patterns in severe disease[8], but have not 
yet described the clinical details of the study population.  
 
We now provide detailed clinicopathological analysis of the MOSAIC cohort, 
segregating patients with and without asthma and confirmed influenza and focusing 
on measures of nasal mucosal and systemic inflammation as potential causes of 
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enhanced disease. Some of the results of this study have been previously reported in 





Study design and cohort 
Adult patients presenting with influenza-like symptoms were recruited between 
December 2009 to March 2011 from 3 hospitals in Liverpool and the Wirral (Northwest 
England) and 6 hospitals in London. A detailed medical history, including the presence 
of a diagnosis of asthma, along with a record of prescribed medications on admission 
was obtained from case notes by specialized data collectors based on Department of 
Health guidelines and continued for the first 14 days of admission[10]. Three patients 
who were coded as having both asthma and COPD were allocated to the non-asthma 
group in order to avoid potential confounding  (one patient had radiological evidence 
of emphysema; the second patient had clinical COPD and bronchiectasis secondary 
to crack-cocaine use and the third patient was clinically coded as having an 
exacerbation of COPD rather than asthma). The severity of respiratory illness was 
graded from 1-3 as previously described[8]. In addition, a panel of 36 healthy 
volunteers (with characteristics described elsewhere[8]) free of comorbidities or 
influenza-like symptoms were recruited to the study and nasal and blood samples 
were obtained at a single time point. 
 
Sample Collection 
Nasopharyngeal aspirates (NPA) and flocked nasopharyngeal swabs were taken as 
soon as possible, generally within 72 hours of admission. Influenza virus infection 
status was assigned on the basis of results of influenza A/B RT-PCRs performed by 
laboratories serving the respective hospitals, with confirmation of these results by RT-
PCR for influenza A, H1N1/2009 and influenza B at the West of Scotland Specialist 
Virology Centre. Antibody responses to A/Engl/195/2009(H1N1v) were detected by 
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use of microneutralization assays according to standard methods as previously 
described[11] at the Centre for Infections, Health Protection Agency (London, UK). 
Serum samples were tested at an initial dilution of 1:10 and a final dilution of 1:5120. 
 
All other samples were collected within 24 hours of admission to the hospital. Blood 
collection and NPA sampling was performed as previously described[8]. Nasosorption 
was used to sample mucosal lining fluid from the nose as detailed previously[12]. 
Additionally, whole blood was collected for microarray RNA profiling (Tempus blood 
RNA tube, Applied Biosystems/Ambion). Research samples were collected within 24 
hours of admission and, where possible, at 48 hours and in convalescence (at least 4 
weeks after presentation).  
 
Sample Processing 
Samples were processed using the ultrasensitive Meso Scale Discovery (MSD) 
platform (Meso Scale Discovery, Gaithersburg, USA), based on electro-
chemiluminescence quantitative patterned arrays to detect 28 cytokines and 
chemokines: IFN-α2α, IFN-β, IFN-γ, IL-29, TNF-α, GMCSF, IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12p70, IL-13, IL-15, IL-17, CCL2, CCL3, CCL4, CCL11, CCL13, CCL17, 
CCL22, CCL26, CXCL8, CXCL9, CXCL10 and CXCL11. Microarray gene expression 
profiling was performed using HT12 V4 BeadChip arrays (Illumina), containing 
>47,000 probes. Detailed methodology is available elsewhere[8].  
 
Statistical Analyses 
Clinical features comparing populations with and without asthma were analysed using 
a combination of two-sided Fisher’s exact test, chi-squared test, unpaired t-test and 
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two-tailed Mann Whitney test as indicated in figure legends. Mediators were compared 
using Kruskal-Wallis and Dunn’s test with Bonferroni multiple correction. Logistic 
regression analysis was carried out to identity independent predictors of severe 
outcome and to investigate association of asthma in relation to severe outcome. All 
analyses were performed with Prism version 7 (Graphpad, La Jolla, California) and R 






Forty of 133 (30.1%) hospitalized adults had asthma (Table 1). Amongst people with 
asthma, influenza A was responsible for 38/40 (95%) cases (all H1) with influenza B 
causing 2/40 (5%) of cases. In individuals without asthma, 82/93 (88.2%) of cases 
were caused by influenza A (H1=77; H3=3; suspected H1 based on serology=1; 
undetermined=1), 10/93 due to influenza B and 1 case with influenza A and B 
coinfection. Females were significantly overrepresented in those with asthma 
compared to those without (70% versus 38.7%, P=0.0012, OR 3.69, 95% CI 1.67 – 
8.18). Patients with asthma had a lower mean length of stay (P=0.0333, 8.3 days 
SEM±2.55 versus 15.3 days SEM±1.82,) and were less likely to require intubation and 
ventilation at peak severity of disease (15% versus 37.6%, P=0.0338, χ2 6.78). 
Relatively few patients with asthma died (5% versus 17.2%, P=0.0944), but were more 
likely to have received the seasonal influenza vaccine (37.5% versus 18.3%, 
P=0.0261) and inhaled corticosteroids (P<0.0001) prior to admission. Following 
admission, people with asthma were more likely to have received at least one dose of 
oral or i.v. corticosteroids during their inpatient stay (55% vs 25.8%, P=0.0016).  
 
To determine predictors of a severe outcome (invasive ventilation or death), multiple 
regression modelling identified presentation to hospital >4 days after symptom onset 
and administration of in-hospital systemic steroids as factors associated with a worse 
outcome (Table E1). When patients with and without a severe outcome were assessed 
separately, presentation to hospital >4 days after symptom onset (P=0.0002, OR 5.49, 
95% CI 2.28 – 14.03) and administration of in-hospital systemic corticosteroids 
(P=0.0466, OR = 2.6250, 95% CI = 1.02 –6.96) remained associated with a severe 
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outcome in people without asthma, but not in those with asthma (data not shown). 
There was no significant difference between individuals with and without asthma in 
nasopharyngeal influenza viral load within 24 hours of admission and kinetics based 
on day of sampling after self-reported onset of influenza-symptoms (Fig. 1a). There 
was also no difference in H1N1 geometric mean titres as measured by 
microneutralization assay (Fig. 1b). 
 
Systemic and Mucosal Immune Response 
All hospitalized patients with influenza had equivalent or greater systemic and mucosal 
inflammation relative to non-hospitalized healthy controls (Fig. 2 and 3, Fig E1 and 
Tables E2-E4). During the first 24 hours of hospital admission, people with asthma 
had reduced systemic inflammation compared to those without as demonstrated by 
significantly lower serum levels of TNF-α (P<0.0001), IL-6 (P=0.0005), CXCL8 
(P<0.0001), CXCL9 (P=0.0031), IL-10 (P=0.0411), IL-17 (P=0.0197) and CCL2 
(P=0.0038); However, individuals with asthma had significantly higher levels of serum 
IFN-α2a (P=0.0099; Fig. 1 and Table E2). Interestingly, those with asthma had lower 
levels of serum IL-5 (P=0.0010) but comparable levels of IL-13 (P=0.3131). There 
were no significant differences in white blood cell count, neutrophils, lymphocytes or 
CRP between groups (figure E1). 
 
There were no significant differences in 28 nasal or nasopharyngeal cytokine and 
chemokine levels measured within 24 hours of admission between individuals with and 
without asthma (Fig. 2, Tables E3 and E4). In particular, there was comparable 
mucosal induction of anti-viral mediators IFN-α2a, IFN-β, IFN-γ, IFN-λ and CXCL10 




Samples from subjects were collected within 24 hours and again at 48-72 after 
admission (if possible). To compare the kinetics of the host immune response to 
infection between patients with and without asthma, mediator levels were assessed 
based on day of illness (DOI), i.e. the interval between subject-reported onset of 
influenza-like symptoms and date of sampling (Figs. E2-4). This analysis showed that 
those without asthma had evidence of greater systemic inflammation with significantly 
higher serum levels of TNF-α (days 3-12), IL-6 (days 4-11), IL-5 (days 11-19), IL-17 
(days 4-7), IL-10 (days 4-8), CCL2 (days 3-5), CXCL8 (days 2-13), CXCL9 (days 5-
12) and CXL10 (days 5-11). In the nasal mucosa, people without asthma had higher 
TNF-α levels (days 8-10) whilst all other mediators demonstrated similar kinetics. 
 
Total IgE (a marker of atopy) and periostin (a marker of IL-4/13 activation) were 
measured in serum, with no significant differences seen between those with and 
without asthma (Fig. 4). The use of pre-admission inhaled corticosteroids in patients 
with asthma (Fig. 5), and administration of systemic corticosteroids within the first 24 
hours of admission in those with and without asthma (Figs. 6 and 7), did not 
significantly affect serum or nasal mucosal levels of IL-5, IL-13 or periostin. 
 
In whole blood RNA, there were no differentially expressed genes (DEG) found 
between individuals with and without asthma after correction for multiple testing (data 
not depicted). Blood eosinophil counts were unavailable, but gene transcripts that 
serve as markers of eosinophilia (CLC, CEBPE, DACH1, EMR1, EMR4P and 
LGALS12[12]) were measured. CEBPE, DACH1 and LGALS12 were not significantly 
different between groups whilst CLC, EMR1 and EMR4P were higher in people without 
 
11 
asthma, indicating that those with asthma in this study were unlikely to have raised 
eosinophil levels (Fig. E5). 
 
Discussion 
In this study, asthma was the major identifiable predisposing condition in patients 
hospitalized with influenza. Influenza cases with asthma tended to be female (70%),  
have a shorter period of hospitalization and a reduced requirement for invasive 
ventilation than those without asthma. Extensive monitoring of mucosal and systemic 
inflammation over time showed relatively low levels of systemic inflammation but equal 
mucosal inflammation in subjects with asthma, compared to those without. 
 
The sex bias noted in this study is reflected in a larger UK based cohort in which 61% 
of asthma patients were female, compared to only 39% of those without asthma[1] 
(personal communication, Puja Miles, Nottingham). It is well described that middle-
aged women have a propensity to present with non-atopic asthma[14], highlighting 
that non-allergic triggers (such as infection) are likely to be key determinants of asthma 
exacerbations in this subgroup. A range of subtypes of asthma have been extensively 
characterized[15]. Many individuals with asthma have increased type 2 inflammation 
associated with mast cell and eosinophil infiltration of the airways[16]. Such patients 
with allergic asthma typically have elevated plasma IL-5 and IL-13, identifying them as 
suitable for biologic therapies that target these cytokines[17, 18]. In addition, IL-5 and 
IL-13 are elevated in nasosorption samples from individuals with allergic asthma (even 
when stable before exacerbation) compared with healthy non-atopic controls[19], as 
well as nasal periostin, IgE and IL-13 in severe asthma[20]. In this study, there was a 
remarkable lack of elevation in serum or nasal type 2 mediators (IL-5 and IL-13) and 
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no significant rise in total serum IgE, periostin and blood eosinophil-specific gene 
expression in individuals with asthma relative to those without asthma. These findings 
raise the possibility that individuals with asthma who are at risk of severe influenza 
may be of a specific disease endotype: females with minimal type 2 inflammation and 
a lack of raised total IgE. This endophenotype is sometimes described as ‘intrinsic’ 
asthma (a classification ascribed to Francis M. Rackemann[21]), who noted that 
intrinsic asthma generally affects older individuals with frequent virally-induced 
exacerbations[22]. However, important caveats to this interpretation are that we do not 
know about other features that predispose to atopy namelythe presence of allergic 
rhinitis or atopic dermatitis symptoms and skin prick or specific IgE responses to 
allergens. Additionally, the pre-existing or convalescent status of type-2 inflammatory 
mediators in both groups are unknown and could therefore have been confounded by 
the presence of influenza infection. 
 
Serosurveys show that the first wave of the 2009 pandemic influenza A H1N1 infected 
one in three children in the UK[11], only a small minority suffering severe disease. The 
role of type 2 cytokines in the pathogenesis of influenza remains unclear. Although T-
helper 2 cells (Th2) are major producers of IL-5 and IL-13[23], other cells may also 
contribute. For example, infection of airway epithelial cells can induce the secretion of 
epithelial-derived cytokines such as IL-25, Thymic stromal lymphopoietin (TSLP) and 
IL-33, which interact with innate lymphoid cells (ILCs) to induce the release of type-2 
cytokines[24, 25]. TSLP induces Type 2 cytokine production even in naive CD4+ cells 
and indirectly affects dendritic cell (DC) function; it may have protective anti-viral 
effects in mice[26]. Influenza infection can enhance production of alveolar 
macrophage derived IL-33, resulting in increased IL-13 release by ILCs and airway 
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hyperreactivity in mice[27]7. IL-33 may also have an important role in epithelial injury 
repair after influenza infection[28][29].  
 
Interferon deficiency has been described in cultured cells from asthma volunteers 
following ex-vivo HRV infection[30–32], whereas robust IFN-γ and IFN-λ responses 
have been found in-vivo during exacerbations in children with asthma[33, 34]. A recent 
study of the effects of fluticasone on bronchial biopsy explants from patients with and 
without asthma infected ex vivo with influenza did not demonstrate any difference in 
epithelial cell infection rates between groups. Whilst there was a reduction in the 
secretion of innate immune mediators (including IFN-γ, CXCL10, MCP-1 and IL-6), 
type-1 IFNs were undetectable[35]. Our current study had the advantages of in vivo 
direct sampling of the blood and airway mucosa, showing increased serum levels of 
IFN-α2a in patients with asthma but comparable levels of interferons (α, β, γ, λ) and 
related chemokines (CXCL10 and CXCL11) in mucosal fluids. Indeed, of all the serum 
proteins measured the only mediator that was increased in patients with asthma 
compared to those without asthma was IFN-α2a. This suggests that patients with 
asthma do not have impaired anti-viral immunity in response to pandemic H1N1 
influenza and the combination of enhanced serum IFN-α2a with a relative lack of 
proinflammatory mediators may have played a protective role amongst those with 
asthma leading to a milder course of disease. 
 
We found that the use of in-hospital systemic corticosteroids was associated with poor 
outcome in those without asthma, but not in those with asthma. A meta-analysis of 
unselected patients with influenza-related complications found that systemic 
corticosteroid use is associated with worse outcomes[36]. More recently, a placebo-
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controlled randomized clinical trial in primary care confirmed the lack of any beneficial 
effect of oral corticosteroids for acute lower respiratory tract symptoms in patients 
without asthma[37]. We found that the use of in-hospital systemic corticosteroids was 
associated with poor outcome in those without asthma, but not in those with asthma. 
However, the fact that corticosteroid use is more prevalent in patients who have 
increased influenza-related complications may have contributed to this association. 
 
Multivariate logistic regression analysis indicated that presentation to hospital ≥4 days 
after symptom onset was associated with worse outcome amongst patients without 
asthma. Individuals with asthma have an abnormal respiratory epithelium with airway 
hyperreactivity (AHR) and may present to hospital primarily due to enhanced mucosal 
responses and bronchospasm. We speculate that the increased number of asthma 
patients being hospitalized with exacerbations may partly be due to early onset of 
respiratory symptoms caused by inflammation in the conducting airways. By contrast, 
people without asthma may present with respiratory failure caused by inflammation in 
the distal gas-exchanging parts of the lung. 
 
A slower decline in viral load has been associated with increased severity of influenza 
infection and immunodysregulation[38]. We found that viral load measured within 24 
hours of admission, subsequent clearance of virus, or serological responses to H1N1 
was not significantly different between patients with and without asthma. This is 
consistent with our conclusions that different systemic immune responses between 
clinical groups are not due to an inability to control viral replication, but rather to 
differences in host response. Antiviral medication (oseltamivir and zanamivir) is 
recommended for those with risk factors for influenza complications, including 
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asthma[39]. Antivirals were very rarely given prior to hospital admission in our patients 
(asthma n=2, non-asthma n=1), so cannot explain differences in immune responses 
measured on admission. They were not administered in 20% of asthma patients in the 
first 24 hours of admission for whom prescribing data was available, but most did 
receive at least one dose during the course of their admission. Other studies show 
that administration of antivirals early during illness and prior to admission significantly 
reduces hospital admission rates[40], and that antivirals within 48 hours of symptom 
onset reduces mortality in hospitalized patients[41]. Our study found that 14/39 
(35.9%) asthma patients and 26/89 (29.2%) patients without asthma received 
antivirals within 48 hours of symptom onset. This may have been due to patients 
presenting later in their illness or a lack of awareness or resources available in primary 
care. Whilst more individuals with asthma received the seasonal influenza vaccine 
compared to those without asthma, vaccination rates were low compared to national 
norms. Immunization with H1N1 vaccine was especially rare, but it is notable that 
some of our cases did appear to have been appropriately vaccinated and yet 
developed severe influenza.  
 
Influenza vaccination coverage in European countries varies widely and use of 
antivirals is patchy, highlighting the need for more effective education programmes for 
both the general population and healthcare providers in early case recognition, and 
consideration of early empirical antiviral therapy to reduce influenza-attributable 
healthcare utilization among patients with asthma[42]. The development of more 
internationally coordinated registries that accurately collate vaccination status along 
with medical and socio-demographic details to assess the impact of public health 




Our study has important limitations. It was designed to investigate all patients admitted 
with influenza rather than to address the issue of the effects of pre-existing asthma on 
the course of influenza. Asthma diagnosis was based on a review of clinical notes and 
patient-reported diagnosis of asthma and we lack spirometric data or information about 
baseline severity and nature of symptoms (e.g. persistent vs. intermittent asthma). We 
do not have blood eosinophil counts, exhaled breath nitric oxide or sputum cell counts. 
Only 40% of asthma patients were on inhaled corticosteroids. However, national 
guidance at the time of recruitment did not require its use in those with mild 
asthma[43]. Additionally, clinical studies recruiting those with confirmed asthma 
commonly have only half of participants taking inhaled corticosteroids[19]. In future 
studies, prospective endophenotyping of asthma patients, coupled with the 
measurement of mucosal and systemic immune parameters might further enhance 
understanding of mechanisms of disease during viral exacerbations[44]. Large cohort 
studies with well-characterized subjects such as the Severe Asthma Research 
Programme (SARP)[45] and Unbiased BIOmarkers in PREDiction of respiratory 
disease outcomes (U-BIOPRED)[46] have the potential to identify how underlying 
endophenotypes influence susceptibility to infection and predict treatment response. 
Despite its limitations, we wish to report our findings in relation to asthma because of 
the unique nature of the MOSAIC study and the likelihood that an opportunity to study 
a pandemic in this way may not arise again. 
 
In summary, our study suggests that patients with asthma hospitalized with influenza 
are predominantly female and have a good prognosis, with reduced systemic 
inflammation but comparable mucosal responses to individuals without asthma. 
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Notably, serum total IgE levels and nasal IL-5 and IL-13 levels were not statistically 
different between patients with and without asthma. Our study highlights the value of 
assessing the airway mucosal and systemic host immune response to influenza, 
suggesting investigation of prospective targeted therapeutic and preventative 
strategies in well-characterized asthma patients with intrinsic disease. 
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Clinical Feature Asthma N (%) No asthma N (%) P value OR / χ2 95% CI 
Total Participants 40 (30%) 93 (70%) - - - 
DEMOGRAPHICS 
Gender (Female) 28 (70%) 36 (38.7%) 0.0012 3.69 1.67-8.18 
Age 18-30a 11 (27.5%) 26 (30.0%) 
0.9699 0.06 NA 
Age 31-45a 14 (35%) 32 (34.4%) 
Age 46-60a 11 (27.5%) 23 (24.7%) 
Age >60a 4 (10%) 12 (12.9%) 
Whitea 27 (67.5%) 62 (66.7%) 
0.5810 1.96 NA 
Asian/Asian Britisha 1 (2.5%) 8 (8.6%) 
Black/ Black Britisha 8 (20%) 14 (15.1%) 
Chinesea 4 (10%) 9 (9.7%) 
COMORBIDITIES & CO-FACTORS 
Any comorbidities other than asthma 25 (62.5%) 62 (66.7%) 0.6930 0.83 0.71-1.24 
Chronic pulmonary conditions exc. 
asthma/COPD 
3 (7.5%) 11 (11.8%) 
0.5519 0.60 0.16-2.30 
Chronic neurological disorders 2 (5%) 6 (6.5%) 1.0000 0.76 0.15-3.96 
Chronic renal disease 3 (7.5%) 5 (5.4%) 0.6965 1.43 0.32-6.28 
Chronic hepatic disease 1 (2.5%) 4 (4.3%) 1.0000 0.57 0.06-5.27 
Chronic cardiovascular disease 10 (25%) 19 (20.4%) 0.6478 1.30 0.54-3.12 
Diabetes 5 (12.5%) 9 (9.7%) 0.7587 1.33 0.42-4.26 
Chronic obesity 10 (25%) 17 (18.3%) 0.4809 1.49 0.61-3.62 
HIV positivity 7 (17.5%) 8 (8.6%) 0.1466 2.25 0.76-6.71 
Immunodeficiency (excluding HIV) 9 (22.5%) 15 (16.1%) 0.4615 1.51 0.60-3.81 
Current or active cancer 3 (7.5%) 19 (20.4%) 0.0778 0.32 0.09-1.14 
Haematological disorder 0 5 (5.4%) 0.3217 0.20 0.01-3.68 
Current or ex-smoker 17/34 (50%) 37/69 (53.6%) 0.8344 0.86 0.38-1.97 
Current Smoker 13/34 (38.2%) 22/69 (31.9%) 0.5106 1.38 0.59-3.24 
Pregnancy (in women of child-bearing age) 3/23 (13%) 10/30 (33.3%) 0.1151 0.30 0.07-1.26 
Seasonal Vaccine 15 (37.5%) 17 (18.3%) 0.0261 2.68 1.17-6.14 
H1N1 Vaccine 8 (20%) 7 (7.5%) 0.0684 3.07 1.03-9.16 
Pre-admission Inhaled corticosteroids 16 (40%) 6 (6.5%) <0.0001 9.67 3.41-27.4 
ADMISSION 
Oral/i.v. corticosteroids on day 1 of admission 15 (37.5%) 13 (14%) 0.0046 3.69 1.55-8.80 
In-hospital oral/i.v. corticosteroid use (≥ 1 dose) 22 (55%) 24 (25.8%) 0.0016 3.51 1.62-7.29 
Admission ≤2 days after symptom onset 15 (37.5%) 32 (34.4%) 0.8435 1.14 0.53-2.47 
Admission ≤4 days after symptom onset 24 (60%) 49 (52.7%) 0.4547 1.35 0.63-2.86 
Days between onset of symptoms and 
admission Median (IQR)b 
3 (2-7) 4 (2-8) 
0.3941 - - 
O2 saturation on admission ≤92% 6/33 (18.2%) 23/71 (32.4%) 0.2389 0.48 0.18-1.37 
Oxygen administered 8/26 (30.1%) 28/63 (44.4%) 0.3423 0.56 0.21-1.47 
Pneumonia on CXR 3/20 (15%) 14/47 (29.8%) 0.2382 0.42 0.11-1.65 
Antibiotic use at admission 28/33 (84.8%) 69/73 (94.5%) 0.1329 0.33 0.08-1.30 
Peak Respiratory Score 1a 15 (37.5%) 27 (29.0%) 
0.0338 6.78 NA Peak Respiratory Score 2a 19 (47.5%) 31 (33.3%) 
Peak Respiratory Score 3a 6 (15%) 35 (37.6%) 
Length of stay (days, mean ±SEM)c 8.3 ±2.55 15.3 ±1.82 0.0333 - - 
Influenza A positivea 38 (95%) 82 (88.2%) 
0.4492 1.60 - Influenza B positivea 2 (5%) 10 (10.8%) 
Influenza A+B co-infectiona 0 1  (1.1%) 
Influenza H1 positivea 38/38 (100%) 77/82 (94.0%) 
0.4903 2.42 - 
Influenza H3 positivea 0 3/82 (3.7%) 
Undetermineda 0 1/82 (1.2%) 
Suspected influenza H1 based on serologya 0 1/82 (1.2%) 
Rhinovirus positive 1/36 (2.8%) 9/83 (10.84%) 0.2788 0.23 0.03-1.93 
Pre-hospital anti-viral use 2/33 (6%) 1/77 (1.3%) 0.2137 4.90 0.43-56.1 
In-hospital antiviral use (≥ 1 dose) 37/39 (94.9%) 85/89 (95.5%) 0.9999 0.87 0.20-4.74 
Antiviral use ≤48 hours from onset of symptoms 14/39 (35.9%) 26/89 (29.2%) 0.5351 1.36 0.62-3.05 
Antiviral use on day 1 of admission  28/35 (80%) 62/73 (84.9%) 0.58 0.71 0.27-1.87 
Positive for any bacteria 0-4 days post onset of 
symptoms (PCR or culture) 
10 (25%) 20/92 (21.7%) 
0.6595 1.20 0.50-2.87 
Positive for any bacteria 5-10 days post onset of 
symptoms (PCR or culture) 
11 (27.5%) 25/92 (27.2%) 
1.000 1.02 0.44-2.34 
Positive for any bacteria 11+ days post onset of 
symptoms (PCR or culture) 
13 (32.5%) 19/92 (20.7%) 
0.1849 1.85 0.80-4.25 
Death 2 (5%) 16 (17.2%) 0.0944 0.25 0.06-1.16 
 
Table 1 Clinical features of hospitalized influenza participants with and without asthma All statistical analyses 
done using Fisher’s exact test unless indicated otherwise. achi-squared test; bMann-Whitney test; cunpaired t-test; 
SEM=standard error of mean. 6 patients without asthma on pre-admission inhaled corticosteroids had comorbidities 
including COPD (n=4) and chronic lung disease (n=2). Note where there is incomplete data about medication and 





Figure 1 | Nasopharangeal influenza viral load and serological response to H1N1 in subjects with and 
without asthma. (a) Viral load kinetics based on number of days elapsed between subject-reported symptom 
onset and time of sampling. Dots represent individual samples with up to 2 samples collected per subject; red 
dots represent asthma (n=37), blue dots represent no asthma (n=88). First sample collected within 24 hours of 
admission and second sample between 48-72 hours of admission to a MOSAIC hospital. Locally weighted 
scatterplot smoothing (LOESS) fits plotted in red for asthma samples and blue for non-asthma samples. Solid 
line represent LOESS fit and dashed lines 95% CI (b) H1N1 geometric mean titre as measured by 
microneutralization assay. Horizontal line represents the geometric mean and error bars the 95% CI. Statistical 








































































































Figure 2: Serum mediators measured within 24 hours of admission to hospital in individuals with and 
without asthma.  Dots represent individual patients (HC=36, asthma=39, no asthma=91) and error bars the 
median and interquartile range. Statistical analysis performed using Kruskal-Wallis and Dunns test with 
Bonferroni multiple correction; *P<0.05; ** P<0.01; *** P <0.001; **** P <0.0001. Abbreviations: HC=Healthy 










































































































Figure 3: Nasal mediators measured within 24 hours of admission to hospital in individuals with and 
without asthma. Dots represent individual patients (HC=36, asthma=40, no asthma=92) and error bars the 
median and interquartile range. Statistical analysis performed using Kruskal-Wallis and Dunns test with 
Bonferroni multiple correction. * P<0.05, ** P<0.01, *** P<0.001, **** P <0.0001. Abbreviations: HC=Healthy 




Figure 4 | Serum levels of Total IgE and periostin in subjects with and without asthma (a) Total serum 
IgE and (b) serum periostin levels measured within 24 hours of admission in individual subjects, asthma (n=37), 
no asthma (n=92). Horizontal bar represents the median and error bars the interquartile range. Statistical 
analysis performed using Mann-Whitney test. 
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Figure 5 | Type 2 inflammatory response in subjects with asthma based on presence or absence of pre-
admission inhaled corticosteroids (a) Nasal IL-5 and (b) nasal IL-13 levels measured within 24 hours of 
admission; subjects on pre-admission inhaled corticosteroids (n=16), subjects not on pre-admission inhaled 
corticosteroids (n=24). (c) Serum IL-5 and (d) serum IL-13 levels measured within 24 hours of admission; 
subjects on pre-admission inhaled corticosteroids (n=16), subjects not on pre-admission inhaled corticosteroids 
(n=23). (e) Serum periostin levels measured within 24 hours of admission; subjects on pre-admission inhaled 
corticosteroids (n=15), subjects not on pre-admission inhaled corticosteroids (n=22). Horizontal bar represents 











































































Figure 6 | Type 2 inflammatory response in subjects with asthma based on administration of oral/I.V. 
corticosteroids within 24 hours of admission (a) Nasal IL-5 and (b) nasal IL-13 levels measured within 24 
hours of admission; subjects on oral/I.V. corticosteroids (n=15), subjects not on oral/I.V. corticosteroids (n=25). 
(c) Serum IL-5 and (d) serum IL-13 levels measured within 24 hours of admission; subjects on oral/I.V. 
corticosteroids (n=15), subjects not on oral/I.V. corticosteroids (n=24). (e) Serum periostin levels measured 
within 24 hours of admission; subjects on oral/I.V. corticosteroids (n=14), subjects not oral/I.V. corticosteroids 
(n=23). Horizontal bar represents the median and error bars the interquartile range. Statistical comparison 
















































































Figure 7 | Type 2 inflammatory response in subjects without asthma based on administration of oral/I.V. 
corticosteroids within 24 hours of admission Nasal IL-5 and (b) nasal IL-13 levels measured within 24 hours 
of admission; subjects on oral/I.V. corticosteroids (n=13), subjects not on oral/I.V. corticosteroids (n=79). (c) 
Serum IL-5 and (d) serum IL-13 levels measured within 24 hours of admission; subjects on oral/I.V. 
corticosteroids (n=13), subjects not on oral/I.V. corticosteroids (n=78). (e) Serum periostin levels measured 
within 24 hours of admission; subjects on oral/I.V. corticosteroids (n=13), subjects not oral/I.V. corticosteroids 
(n=77). Horizontal bar represents the median and error bars the interquartile range. Statistical comparison 
performed using Mann-Whitney test 
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Table E1 | Multivariate logistic regression model of covariates associated with severe outcome 
Table E2 | Serum cytokines and chemokines measured within 24 hours of admission 
Table E3 | Nasal cytokines and chemokines measured within 24 hours of admission 
Table E4 | Nasopharyngeal cytokines and chemokines measured within 24 hours of admission 
Figure E1 | Serum level of CRP measured within 24 hours of admission 
Figure E2 | Scatterplots of serum mediators differentiated by day of illness (DOI)  
Figure E3 | Scatterplots of nasal mediators differentiated by day of illness (DOI)  
Figure E4 | Scatterplots of nasopharyngeal mediators differentiated by day of illness (DOI) 





 n=133  
Table E1 | Multivariate logistic regression model of covariates associated with severe 
outcome 
Outcome: Death or respiratory failure 
requiring invasive ventilation 
P-value Adjusted OR 95% CI 
Asthma Present 0.0521 0.2947 0.0790 - 0.9537 
Gender (female as reference) 0.2862 1.6550 0.6611 - 4.2674 
Age (18-30 years as reference)  
Age 31-40 0.8939 1.0944 0.2847 - 4.1500 
Age 41-50 0.6043 1.3669 0.4215 - 4.5728 
Age >50 0.0818 3.1190 0.8890 - 11.7696 
Admission >4 days 0.0001 5.9084 2.4540 - 15.4449 
Seasonal flu vaccination 0.1342 0.4002 0.1120 - 1.2664 
Inhaled corticosteroid use 0.2068 0.3573 0.0621 - 1.6321 
Oral/I.V. corticosteroids 0.0154 3.4629 1.3036 - 9.9038 
 
36 
HC=Healthy control; A=Asthma; NA=No Asthma 
  



















A vs NA A vs HC NA vs HC  
IFN-α2α 5.31 8.08 5.07 0.0099 0.0452 1.000  
IFN-β 11.67 11.67 11.67 1.000 0.0042 0.0021  
IFN-γ 0.32 1.38 2.32 0.1256 0.0806 0.0001  
IFN –λ/IL-29 26.84 12.01 12.01 1.0000 0.3816 0.1327  
 
TNF-α 5.17 4.67 6.64 0.0000 0.5235 0.0015  
GMCSF 1.06 0.29 0.76 0.4591 0.8004 1.0000  
 
IL-1β 0.78 0.33 0.33 0.2631 1.0000 0.3032  
IL-2 4.70 5.09 6.23 0.0906 1.0000 0.2109  
IL-4 1.66 0.90 1.02 1.0000 0.0038 0.0011  
IL-5 1.06 0.77 1.42 0.0010 0.2020 0.1791  
IL-6 3.78 9.98 38.81 0.0005 0.0004 0.0000  
IL-10 1.48 4.59 7.49 0.0411 0.0001 0.0000  
IL-12p70 3.99 1.75 1.98 0.8897 0.0145 0.0177  
IL-13 1.22 2.64 2.91 0.3131 0.0004 0.0000  
IL-15 1.63 3.71 4.81 0.1809 0.0000 0.0000  
IL-17 3.20 5.56 7.58 0.0197 0.0003 0.0000  
 
CCL2/ MCP-1 415.82 435.19 595.56 0.0038 1.0000 0.0027  
CCL3/ MIP-1α 10.99 13.49 13.69 1.0000 0.0725 0.0166  
CCL4/ MIP-1β 165.28 125.66 133.52 0.7915 0.0179 0.0291  
CCL11/ Eotaxin 1250.70 547.81 621.48 1.0000 0.0002 0.0000  
CCL13/ MCP-4 640.96 357.80 394.07 0.8654 0.0017 0.0016  
CCL17/ TARC 412.83 263.25 240.04 1.0000 0.0020 0.0007  
CCL22/ MDC 4010.90 1381.39 1739.56 0.5969 0.0000 0.0000  
CCL26/ Eotaxin-3 2.51 15.75 18.36 0.8089 0.0000 0.0000  
CXCL8/ IL-8 7.61 10.99 25.78 0.0000 0.0643 0.0000  
CXCL9/ MIG 44.64 68.72 114.22 0.0031 0.0016 0.0000  
CXCL10/ IP-10 167.09 721.01 1409.26 0.0546 0.0000 0.0000  
CXCL11/ ITAC 60.98 187.57 277.71 0.2949 0.0000 0.0000  
 
37 
HC=Healthy control; A=Asthma; NA=No Asthma 
  
Table E3 | Nasal cytokines and chemokines measured within 24 hours of admission 














Dunn’s test with Bonferroni correction; P-
value 
 
A vs NA A vs HC NA vs HC 
IFN-α2a 1.31 1.31 1.31 1.0000 0.0000 0.0000 
IFN-β 66.05 41.02 49.52 0.7356 0.0604 0.1247 
IFN-γ  0.32 1.36 1.60 1.0000 0.0496 0.0495 
IFN-λ (IL-29) 12.01 12.01 12.01 1.0000 0.0000 0.0000 
 
TNF-α 1.31 1.83 3.86 0.0674 0.0312 0.0000 
GMCSF 1.17 1.63 1.58 0.7172 0.1926 0.0208 
 
IL-1β 31.11 28.03 25.36 1.0000 0.9505 1.0000 
IL-2 1.93 2.47 3.49 0.7123 1.0000 0.8696 
IL-4 0.40 0.40 0.40 0.2432 0.0000 0.0000 
IL-5 1.04 0.65 0.95 0.7025 0.2192 0.4762 
IL-6 12.26 54.78 125.68 0.4013 0.0000 0.0000 
IL-10 0.78 1.58 1.99 1.0000 0.0041 0.0001 
IL-12p70 1.51 1.12 1.45 0.3472 0.3515 1.0000 
IL-13 0.76 3.09 2.33 0.1510 0.0000 0.0002 
IL-15 1.17 2.26 1.94 0.6601 0.0103 0.0235 
IL-17 7.06 9.67 9.01 0.5367 0.2055 0.5915 
 
CCL2/ MCP-1 49.16 160.36 161.93 0.7861 0.0014 0.0000 
CCL3/ MIP-1α 8.65 28.61 29.41 1.0000 0.0000 0.0000 
CCL4/ MIP-1β 23.33 92.86 135.37 0.6431 0.0005 0.0000 
CCL11/ Eotaxin 138.53 253.14 229.45 0.3149 0.0000 0.0000 
CCL13/ MCP-4 12.35 13.00 12.88 1.0000 0.4939 0.3527 
CCL17/ TARC 4.96 17.67 14.37 0.3462 0.0543 0.2938 
CCL22/ MDC 115.93 157.02 158.61 1.0000 0.3130 0.1788 
CCL26/ Eotaxin-3 30.91 44.17 38.45 1.0000 0.4245 0.2513 
CXCL8/ IL-8 1880.12 2177.42 2326.43 1.0000 1.0000 1.0000 
CXCL9/ MIG 212.28 561.13 525.16 0.1771 0.0037 0.0625 
CXCL10/ IP-10 773.80 5215.96 4619.65 0.2013 0.0000 0.0000 
CXCL11/ ITAC 11.65 126.69 64.50 0.1026 0.0000 0.0010 
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HC=Healthy control; A=Asthma; NA=No Asthma 
  
Table E4 | Nasopharyngeal cytokines and chemokines measured within 24 hours of 
admission 
 














Dunn’s test with Bonferroni correction; P-
value 
 
A vs NA A vs HC NA vs HC 
IFN-α2a 1.31 1.31 1.31 0.2611 0.0016 0.0000 
IFN-β 11.67 11.67 11.67 1.0000 0.0394 0.0386 
IFN-γ  0.32 1.05 0.32 0.2193 0.6190 0.8937 
IFN-λ (IL-29) 12.01 12.01 12.01 0.5483 0.0000 0.0000 
 
TNF-α 0.30 7.90 7.11 1.0000 0.0000 0.0000 
GMCSF 0.29 2.01 2.42 1.0000 0.0000 0.0000 
 
IL-1β 0.33 4.76 3.21 1.0000 0.0000 0.0000 
IL-2 0.58 5.27 10.08 0.6876 0.0088 0.0001 
IL-4 0.40 0.40 1.23 0.7800 1.0000 0.9828 
IL-5 0.30 0.90 0.78 1.0000 0.6427 0.6659 
IL-6 0.33 10.55 34.27 0.9277 0.0000 0.0000 
IL-10 0.28 0.80 0.61 1.0000 0.0000 0.0000 
IL-12p70 0.29 1.39 1.13 1.0000 0.2038 0.0796 
IL-13 0.78 2.78 1.76 0.2548 0.0000 0.0000 
IL-15 0.31 0.66 0.47 1.0000 1.0000 1.0000 
IL-17 0.25 9.09 5.20 0.5273 0.0000 0.0000 
 
CCL2/ MCP-1 1.70 66.62 123.56 1.0000 0.0000 0.0000 
CCL3/ MIP-1α 1.37 28.04 26.42 1.0000 0.0000 0.0000 
CCL4/ MIP-1β 5.25 279.03 135.08 0.8527 0.0076 0.0001 
CCL11/ Eotaxin 14.98 850.31 536.97 1.0000 0.0000 0.0000 
CCL13/ MCP-4 2.94 38.24 38.26 1.0000 0.0000 0.0000 
CCL17/ TARC 4.96 47.84 29.73 0.5485 0.0000 0.0000 
CCL22/ MDC 54.39 435.31 375.91 0.8612 0.0000 0.0000 
CCL26/ Eotaxin-3 2.51 26.86 17.95 1.0000 0.0000 0.0000 
CXCL8/ IL-8 10.40 2173.69 888.60 1.0000 0.0000 0.0000 
CXCL9/ MIG 2.52 360.53 216.47 0.9507 0.0000 0.0000 
CXCL10/ IP-10 11.98 9004.99 3389.03 0.7205 0.0000 0.0000 

































































































Figure E1 | Serum white cell count differential and CRP levels in subjects with and without asthma 
Measured within 24 hours of admission in individual subjects: (a) white cell count (asthma n=37, no asthma 
n=84), (b) neutrophils (asthma n=36 , no asthma n=82), (c) lymphocytes (asthma n=33, no asthma n=79) and 
CRP (asthma n=37, no asthma n =90) Horizontal bar represents the median and error bars the interquartile 






Figure E2 | Scatterplots of serum mediators differentiated by day of illness (DOI)  
Dots represent individual samples up to two samples collected per subject. Red dots represent asthma (n=64), 
blue dots represent no asthma (n=155). First sample collected within 24 hours of admission and second sample 
between 48-72 hours of admission. DOI represents number of days elapsed between subject-reported symptom 
onset and time of sampling. Locally weighted scatterplot smoothing (LOESS) fits plotted in red for asthma 





Figure E3 | Scatterplots of nasal mediators differentiated by day of illness (DOI)  
Dots represent individual samples with up to two samples collected per subject. Red dots represent asthma 
(n=65), blue dots represent no asthma (n=153). First sample collected within 24 hours of admission and second 
sample between 48-72 hours of admission. DOI represents number of days elapsed between subject-reported 
symptom onset and time of sampling. Locally weighted scatterplot smoothing (LOESS) fits plotted in red for 





Figure E4 | Scatterplots of nasopharyngeal mediators differentiated by day of illness (DOI)  
Dots represent individual samples up to two samples collected per subject. Red dots represent asthma (n=49), 
blue dots represent no asthma (n=123). First sample collected within 24 hours of admission and second sample 
between 48-72 hours of admission. Day of illness represents number of days elapsed between subject-reported 
symptom onset and time of sampling. Locally weighted scatterplot smoothing (LOESS) fits plotted in red for 






Figure E5 | Expression of eosinophil associated genes in subjects with and without asthma Whole blood 
samples were collected within 24 hours of admission for gene expression. RNA was extracted and analysed 
using Illumina microarray and the data normalized. Dots represent individual patients (asthma=33, no 
asthma=74) with horizontal bar representing the mean and error bars the 95% CI. Statistical analysis performed 
using unpaired t-test 
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